| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on September 13, 2006
Accepted on December 26, 2006
University of Manchester, UK; "Tor Vergata" University, Rome, Italy; Robert Debre Hospital, Paris, France; Sahlgrenska University Hospital, Gothenburg, Sweden; Mount Sinai School of Medicine, New York, USA; University of Virginia, Charlottesville, USA
* To whom correspondence should be addressed. E-mail: arogol{at}cstone.net.
Objective: Low birth weight (LBW) remains a major cause of morbidity and mortality in early infancy and childhood. It is associated with an increased risk of health problems later in life, in particular coronary heart disease and stroke. A meeting was convened to identify the key health issues facing a child born small-for-gestational age (SGA) and to propose management strategies.
Participants: There were 42 participants chosen for their expertise in obstetrics, peri- and neonatal medicine, paediatrics, paediatric and adult endocrinology, epidemiology and pharma.
Evidence: Written materials were exchanged, reviewed, revised and then made available to all. This formed the basis for discussions at the meeting. Where published data were not available or adequate, discussion was based on expert clinical opinions.
Consensus Process: Each set of questions was considered by all, and then discussed in plenary with consensus and unresolved issues identified. The consensus statement was prepared in plenary session and then edited by the group chairs and shared with all participants.
Conclusions: The diagnosis of SGA should be based on accurate anthropometry at birth including weight, length and head circumference. We recommend early surveillance in a growth clinic for those without catch-up. Early neurodevelopment evaluation and interventions are warranted in at-risk children. Endocrine and metabolic disturbances in the SGA child are recognised, but infrequent. For the 10% who lack catch-up, GH treatment can increase linear growth. Early intervention with GH for those with severe growth retardation (height SDS <-2.5, age 2-4 y) should be considered at a dose of 35-70µg/kg/day. Long-term surveillance of those treated is essential. The associations at a population level between LBW, including SGA, and coronary heart disease and stroke in later life are recognised, but there is inadequate evidence to recommend routine health surveillance of all adults born SGA, outside of normal clinical practice.
This article has been cited by other articles:
 |
|
 |
|
  P. Cohen, A. D. Rogol, C. L. Deal, P. Saenger, E. O. Reiter, J. L. Ross, S. D. Chernausek, M. O. Savage, J. M. Wit, and on behalf of the 2007 ISS Consensus Workshop parti Consensus Statement on the Diagnosis and Treatment of Children with Idiopathic Short Stature: A Summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop J. Clin. Endocrinol. Metab., November 1, 2008; 93(11): 4210 - 4217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Meas, S. Deghmoun, P. Armoogum, C. Alberti, and C. Levy-Marchal Consequences of Being Born Small for Gestational Age on Body Composition: An 8-Year Follow-Up Study J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3804 - 3809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Willemsen, S. P. Willemsen, and A. C. S. Hokken-Koelega Longitudinal Changes in Insulin Sensitivity and Body Composition of Small-For-Gestational-Age Adolescents after Cessation of Growth Hormone Treatment J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3449 - 3454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Binder, A.-K. Seidel, D. D. Martin, R. Schweizer, C. P. Schwarze, H. A. Wollmann, T. Eggermann, and M. B. Ranke The Endocrine Phenotype in Silver-Russell Syndrome Is Defined by the Underlying Epigenetic Alteration J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1402 - 1407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. J. de Ridder, T. Stijnen, and A. C. S. Hokken-Koelega Prediction Model for Adult Height of Small for Gestational Age Children at the Start of Growth Hormone Treatment J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 477 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Argente, R. Gracia, L. Ibanez, A. Oliver, E. Borrajo, A. Vela, J. P. Lopez-Siguero, M. L. Moreno, F. Rodriguez-Hierro, and on behalf of the Spanish SGA Working Group Improvement in Growth after Two Years of Growth Hormone Therapy in Very Young Children Born Small for Gestational Age and without Spontaneous Catch-Up Growth: Results of a Multicenter, Controlled, Randomized, Open Clinical Trial J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3095 - 3101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E M Delemarre, J Rotteveel, and H A D.-v. de Waal Metabolic implications of GH treatment in small for gestational age Eur. J. Endocrinol., August 1, 2007; 157(suppl_1): S47 - S50. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Saenger, P. Czernichow, I. Hughes, and E. O. Reiter Small for Gestational Age: Short Stature and Beyond Endocr. Rev., April 1, 2007; 28(2): 219 - 251. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
